Get to know our clinical trials
A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GS-1811, an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti¿PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors
- A PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF GS-1811, AN AFUCOSYLATED ANTI-CCR8 MONOCLONAL ANTIBODY, AS MONOTHERAPY AND IN COMBINATION WITH AN ANTI&IQUEST;PD-1 MONOCLONAL ANTIBODY IN ADULTS WITH ADVANCED SOLID TUMORS
- Code EudraCT: -
- Protocol number: GS-US-570-6015
- Promoter: Gilead Science
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.